Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Inclusion Criteria:

* Patients must have persistent, metastatic, or recurrent platinum resistant or refractory ovarian or primary peritoneal cancer.
* No restriction on previous treatment regimens, but patients must be at least 2 weeks out from last chemotherapy or investigational agent.
* Patients must be \>= 18.
* Patients must have a life expectancy of at least 6 months.
* Patients must have KPS \>= 60.
* Patients must have acceptable organ and marrow function as defined below (within 2 weeks prior to radiotherapy):

  * leukocytes \>=3,000/uL
  * absolute neutrophil count \>=1,500uL
  * platelets \>=100,000/uL
  * total bilirubin within 1.5X normal institutional limits
  * AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal
  * creatinine within normal institutional limits OR
  * creatinine clearance \>=60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
* Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients should not have received radiation overlapping with the proposed treatment field.
* Patients cannot be receiving chemotherapy or other investigation agents from two weeks prior to radiation through undergoing their post-therapy FDG-PET/CT
* Patients cannot be pregnant or nursing.
* Patients cannot have disease \>= 8cm or greater than 3 regions of disease.
* Patients cannot have concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, or carcinoma in situ of the cervix.